GSK3640254

DRUG10 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

CompletedNCT03231943

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2017-09-19End: 2018-09-09Updated: 2021-06-10

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

CompletedNCT03816696

ViiV HealthcareHIV Infections

Start: 2019-01-23End: 2019-04-10Updated: 2020-03-19

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

CompletedNCT03836729

ViiV HealthcareHIV Infections

Start: 2019-02-11End: 2019-04-30Updated: 2020-04-21

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

CompletedNCT03984825

ViiV HealthcareHIV Infections

Start: 2019-06-13End: 2019-08-16Updated: 2020-08-27

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

CompletedNCT04563845

ViiV HealthcareHIV Infections

Start: 2020-11-09End: 2021-10-30Updated: 2023-12-06

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

CompletedNCT04630002

ViiV HealthcareHIV Infections

Start: 2020-10-28End: 2021-10-02Updated: 2024-08-29

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

CompletedNCT04857892

ViiV HealthcareHIV Infections

Start: 2021-04-21End: 2021-09-10Updated: 2024-03-12

Phase 2

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

CompletedNCT03784079

ViiV HealthcareHIV Infections

Start: 2019-01-31End: 2020-02-06Updated: 2021-02-16

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

TerminatedNCT04493216

ViiV HealthcareHIV Infections

Start: 2020-11-18End: 2023-05-29Updated: 2024-06-26

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

TerminatedNCT04900038

ViiV HealthcareHIV Infections

Start: 2021-08-18End: 2023-05-11Updated: 2023-12-14

Related Papers

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

2025-10-17

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study.

2025-10-17

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Clinical Pharmacology in Drug Development2022-01-075 citations

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

Clinical Infectious Diseases2022-01-0520 citations

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.

2021-05-1812 citations

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor

Pharmacology Research & Perspectives2020-11-1728 citations